Reduction of Blood Recirculation in Veno-Venous ECMO

November 13, 2026 updated by: Steffen Weber-Carstens, Charite University, Berlin, Germany

Reduction of Blood Recirculation in Veno-Venous ECMO Through Ultrasound Dilution Measurements (ECMO Circulation Study)

Blood which recirculates through the circuit of a veno-venous Extracorporeal Membrane Oxygenation (V-V ECMO) does not contribute to the systemic oxygenation of a patient on V-V ECMO and is called the recirculation fraction (Rf). Theoretically, the optimization of ECMO blood flow is possible using Rf measurements.

A prospective, observational study will be performed measuring the Rf of total ECMO blood flow in patients with acute respiratory distress syndrome (ARDS) on V-V ECMO with an ultrasound dilution technique.

ECMO blood flow will be optimized by reducing ECMO blood flow in accordance with the measured Rf as long as systemic oxygenation is not compromised.

Study Overview

Status

Completed

Conditions

Detailed Description

Based on data from the 'Blood Recirculation and vvECMO' trial (ClinicalTrials.gov ID: NCT03200314) (i.e. an expected frequency of successful blood flow reduction of 66.7%), using a one-sample Chi square test, a two-sided type-1 error of 5%, a power of 80%, a total of 68 patients is needed to show that the proportion of patients with a secure ECMO blood flow reduction is greater than 50%. Presumably, 136 Patients have to be included into the trial to study 68 patients with a relevant Rf since not all patients on V-V ECMO suffer from a high Rf.

Study Type

Observational

Enrollment (Actual)

77

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • State of Berlin
      • Berlin, State of Berlin, Germany, 13353
        • Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Inclusion Criteria:

  • patients aged 18 years or older
  • ARDS
  • veno-venous ECMO

Exclusion Criteria:

  • age < 18 years
  • hemodynamic instability during measurement of recirculation
  • pregnancy
  • inability to obtain patient's consent or consent of legal guardian

Description

Patients aged 18 years or older requiring veno-venous ECMO for treatment of refractory hypoxemia in ARDS.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Successful ECMO blood flow reduction
Time Frame: Once within the first week after initiation of ECMO therapy

Number of patients with a relevant recirculation fraction and successful ECMO blood flow reduction

Once within the first week after initiation of ECMO therapy

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Recirculation fraction
Time Frame: Once within the first week after initiation of ECMO therapy

Fraction of blood recirculating through the ECMO circuit

Once within the first week after initiation of ECMO therapy
Arterial blood oxygen content
Time Frame: Once within the first week after initiation of ECMO therapy

Arterial blood oxygen content before vs. after reduction of ECMO blood flow

Once within the first week after initiation of ECMO therapy
Extracorporeal blood Flow
Time Frame: Once within the first week after initiation of ECMO therapy

ECMO Blood Flow before vs. after reduction of ECMO blood flow

Once within the first week after initiation of ECMO therapy
Extracorporeal gas flow
Time Frame: Once within the first week after initiation of ECMO therapy

ECMO Sweep Gas flow

Once within the first week after initiation of ECMO therapy
Length of ECMO therapy
Time Frame: Daily until the end of ECMO therapy (approximately 14 days)

Days on ECMO

Daily until the end of ECMO therapy (approximately 14 days)
Cannula position and distance
Time Frame: Once within the first week after initiation of ECMO therapy

The distance between the tip of drainage and return cannula will be measured in the existing medical imaging (e.g. CT scans)

Once within the first week after initiation of ECMO therapy
Right heart dysfunction
Time Frame: Once within the first week after initiation of ECMO therapy

Existing echocardiography will be evaluated for possible right heart dysfunction

Once within the first week after initiation of ECMO therapy
Length of mechanical ventilation
Time Frame: Entire duration of the ICU stay (approximately 28 days)

Length of mechanical ventilation

Entire duration of the ICU stay (approximately 28 days)
Complications of ECMO therapy
Time Frame: Length of ECMO therapy (approximately 14 days)

Incidence of cannula or system changes (i.e. due to circuit clotting), complications attributed to ECMO therapy like bleeding complications from the cannulation site, transfusion requirements, hemolysis

Length of ECMO therapy (approximately 14 days)
ICU mortality
Time Frame: Entire duration of the ICU stay (approximately 28 days)

ICU mortality

Entire duration of the ICU stay (approximately 28 days)
ICU length of stay
Time Frame: Entire duration of the ICU stay (approximately 28 days)

ICU length of stay

Entire duration of the ICU stay (approximately 28 days)
Incidence of ICU-acquired organ dysfunctions and complications
Time Frame: Entire duration of the ICU stay (approximately 28 days)

Cerebral-, cardiovascular-, cardiac- pulmonary-, gastrointestinal- and renal dysfunctions, ICU-acquired infections

Entire duration of the ICU stay (approximately 28 days)
ECMO blood flow over time
Time Frame: Daily until the end of ECMO therapy (approximately 14 days)

ECMO blood and sweep gas flow over time

Daily until the end of ECMO therapy (approximately 14 days)
ECMO sweep gas flow over time
Time Frame: Daily until the end of ECMO therapy (approximately 14 days)

ECMO sweep gas flow over time

Daily until the end of ECMO therapy (approximately 14 days)
Mobility at ICU discharge
Time Frame: Discharge from the ICU (approximately 28 days)

Level of mobility the patient has reached at ICU discharge (recumbent, sitting, standing, walking with help, walking independently)

Discharge from the ICU (approximately 28 days)
Weaning level at ICU discharge
Time Frame: Discharge from the ICU (approximately 28 days)

Level of weaning reached at ICU discharge

Discharge from the ICU (approximately 28 days)
Status of mechanical ventilation at ICU discharge
Time Frame: Discharge from the ICU (approximately 28 days)

Status of mechanical ventilation at ICU discharge including all relevant settings and parameters

Discharge from the ICU (approximately 28 days)
Level of organ dysfunction at ICU discharge
Time Frame: Discharge from the ICU (approximately 28 days)

Sepsis-related Organ Failure Assessment Score at ICU discharge

Discharge from the ICU (approximately 28 days)
Level of consciousness at ICU discharge
Time Frame: Discharge from the ICU (approximately 28 days)

Glasgow Coma Scale at ICU discharge

Discharge from the ICU (approximately 28 days)
Level of disease severity
Time Frame: Discharge from the ICU (approximately 28 days)

Acute Physiology And Chronic Health Evaluation at ICU discharge

Discharge from the ICU (approximately 28 days)
Hospital acquired infections related to ECMO therapy
Time Frame: Entire duration of ECMO therapy

Infection/colonisation of the ECMO circuit

Entire duration of ECMO therapy
Bleeding and thrombembolic complications of ECMO therapy
Time Frame: Entire duration of ECMO therapy

Bleeding complications, thrombembolic events, overall use of blood products and coagulation factors, electron microscopic evaluation of selected membranes after change or weaning of the ECMO circuit

Entire duration of ECMO therapy

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Martin Russ, Dr. med., Charite University Hospital Berlin
  • Principal Investigator: Philipp A Pickerodt, Dr. med., Charite University Hospital Berlin
  • Principal Investigator: Vladimir Skrypnikov, Dr. med., Charite University Hospital Berlin
  • Principal Investigator: Steffen Weber-Carstens, Prof. Dr. med., Charite University Hospital Berlin

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 20, 2020

Primary Completion (Actual)

May 5, 2026

Study Completion (Actual)

May 5, 2026

Study Registration Dates

First Submitted

September 14, 2020

First Submitted That Met QC Criteria

February 12, 2021

First Posted (Actual)

February 15, 2021

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 13, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • EA115620

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.